Progen liver cancer program accelerates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Progen's recent discussions with FDA suggest that development time for its liver cancer agent PI-88 will be cut by up to three years, Progen announces May 16. In response to FDA's request that the firm submit a special protocol assessment for a Phase III trial, the company plans to advance its current Phase II trial directly to Phase III. The Brisbane, Australia firm notes that "FDA supports a registration approach based on a single pivotal trial" and "an accelerated approval based on meeting the secondary endpoint of disease-free survival." Progen describes PI-88 as a heparan sulfate mimetic; the agent exerts its anti-angiogenic activity by inhibiting VEGF, FGF-1 and FGF-2...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.